losartan has been researched along with Arteriosclerosis in 34 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "To observe the effect of angiotensin II (Ang II) on expression of gap junction channel protein connexin 43 (Cx43) in the proliferation process of vascular smooth muscle cells (VSMCs) during the early stage of arteriosclerosis." | 7.73 | Effects of angiotensin II on connexin 43 of VSMCs in arteriosclerosis. ( Cai, W; Chen, JZ; Ruan, LM; Wang, YN, 2006) |
| " We have recently demonstrated that chronic infusion of Angiotensin II into apoE-/- mice promotes the development of abdominal aortic aneurysms." | 7.71 | Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. ( Cassis, LA; Daugherty, A; Manning, MW, 2001) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "In the femoral circulation of 19 patients with atherosclerosis and of 9 control subjects, we studied microvascular responses to reactive hyperemia, angiotensin II, acetylcholine, and sodium nitroprusside before and after the administration of intra-arterial losartan (10 mg)." | 5.09 | Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. ( Ellahham, S; Mincemoyer, R; Panza, JA; Prasad, A; Quyyumi, AA; Schenke, WH; Tupas-Habib, T; Waclawin, MA, 2000) |
| "To observe the effect of angiotensin II (Ang II) on expression of gap junction channel protein connexin 43 (Cx43) in the proliferation process of vascular smooth muscle cells (VSMCs) during the early stage of arteriosclerosis." | 3.73 | Effects of angiotensin II on connexin 43 of VSMCs in arteriosclerosis. ( Cai, W; Chen, JZ; Ruan, LM; Wang, YN, 2006) |
| " To evaluate this effect in vivo, apolipoprotein E(-/-) mice were randomly assigned to receive standard chow, a high-cholesterol diet, or a high-cholesterol diet with hypertension induced by angiotensin II infusion for 8 weeks." | 3.71 | Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. ( Aikawa, M; Hill, CC; Lee, RT; Libby, P; Sakamoto, H; Taylor, WR; Weiss, D, 2001) |
| " We have recently demonstrated that chronic infusion of Angiotensin II into apoE-/- mice promotes the development of abdominal aortic aneurysms." | 3.71 | Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. ( Cassis, LA; Daugherty, A; Manning, MW, 2001) |
| " This study was designed to determine the effect of hypercholesterolemia on LOX-1 expression in aorta and its modulation by the AT(1) receptor blocker losartan." | 3.70 | Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. ( Chen, H; Inoue, K; Li, D; Mehta, JL; Sawamura, T, 2000) |
| " It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes." | 3.70 | Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000) |
| " Afterward is considered the importance of the administration of the inhibiting of the receptors AT-1 (Losartan) in the control of the hypertension and of the atherosclerosis." | 3.69 | [Physiopathology of angiotensin II and vascular lesion]. ( Marci, M; Raffa, S; Russo, F, 1997) |
| "Losartan treatment reduced lesion area at the aortic sinus, although differences were only significant in female mice." | 1.33 | Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice. ( Catanzaro, DF; Catanzaro, SE; Chen, R; Dansky, HM; Hu, L; Zhou, Y, 2005) |
| "Captopril and quinapril were more effective than losartan in preserving vascular relaxation." | 1.31 | Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. ( Browne, AE; Chatterjee, K; Chou, TM; Deedwania, PC; Glantz, SA; Parmley, WW; Pulukurthy, S; Sudhir, K; Sun, YP; Zhu, BQ, 2001) |
| "Losartan-treated rabbits revealed a reduction in immunohistochemical expression of MMP-1, whereas TIMP-2 expression became localized to the intima." | 1.31 | Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits. ( Chen, H; Li, D; Mehta, JL, 2002) |
| " A low dosage of fosinopril (5 mg/kg/d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure." | 1.30 | The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. ( Attias, J; Breslow, JL; Brodsky, S; Coleman, R; Hayek, T; Keidar, S; Smith, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (20.59) | 18.2507 |
| 2000's | 27 (79.41) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trenkwalder, P | 1 |
| Keidar, S | 5 |
| Kaplan, M | 2 |
| Pavlotzky, E | 1 |
| Coleman, R | 2 |
| Hayek, T | 5 |
| Hamoud, S | 1 |
| Aviram, M | 3 |
| Okigaki, M | 1 |
| Iwasaka, T | 1 |
| Tatsuno, I | 1 |
| Liang, C | 2 |
| Wu, ZG | 1 |
| Ding, J | 1 |
| Jiang, JF | 1 |
| Huang, GZ | 1 |
| Du, RZ | 1 |
| Ge, JB | 1 |
| Ge, J | 1 |
| Huang, D | 1 |
| Luo, Y | 1 |
| Jia, Q | 1 |
| Wang, K | 1 |
| Yoshida, D | 1 |
| Higashiura, K | 1 |
| Shimamoto, K | 1 |
| Zhou, Y | 1 |
| Chen, R | 1 |
| Catanzaro, SE | 1 |
| Hu, L | 1 |
| Dansky, HM | 1 |
| Catanzaro, DF | 1 |
| Fossum, E | 1 |
| Olsen, MH | 1 |
| Høieggen, A | 1 |
| Wachtell, K | 1 |
| Reims, HM | 1 |
| Kjeldsen, SE | 1 |
| Ibsen, H | 1 |
| Wan, Y | 1 |
| Julius, S | 1 |
| Cai, W | 1 |
| Ruan, LM | 1 |
| Wang, YN | 1 |
| Chen, JZ | 1 |
| Nishimura, N | 1 |
| Takase, H | 1 |
| Morita, T | 1 |
| Makita, S | 1 |
| Nakamura, M | 1 |
| Yoshida, H | 1 |
| Hiramori, K | 1 |
| Attias, J | 2 |
| Smith, J | 2 |
| Breslow, JL | 2 |
| Russo, F | 1 |
| Marci, M | 1 |
| Raffa, S | 1 |
| Makaritsis, KP | 1 |
| Gavras, H | 1 |
| Du, Y | 1 |
| Chobanian, AV | 1 |
| Brecher, P | 1 |
| Kranzhöfer, R | 1 |
| Browatzki, M | 1 |
| Schmidt, J | 1 |
| Kübler, W | 1 |
| Brodsky, S | 1 |
| Strawn, WB | 2 |
| Chappell, MC | 1 |
| Dean, RH | 2 |
| Kivlighn, S | 1 |
| Ferrario, CM | 2 |
| Prasad, A | 1 |
| Tupas-Habib, T | 1 |
| Schenke, WH | 1 |
| Mincemoyer, R | 1 |
| Panza, JA | 1 |
| Waclawin, MA | 1 |
| Ellahham, S | 1 |
| Quyyumi, AA | 1 |
| Heinrich, R | 2 |
| Sakhnini, E | 1 |
| Vaughan, D | 1 |
| Chen, H | 2 |
| Li, D | 2 |
| Sawamura, T | 1 |
| Inoue, K | 1 |
| Mehta, JL | 3 |
| Ma, LJ | 1 |
| Nakamura, S | 1 |
| Whitsitt, JS | 1 |
| Marcantoni, C | 1 |
| Davidson, JM | 1 |
| Fogo, AB | 1 |
| Milionis, HJ | 1 |
| Elisaf, MS | 1 |
| Kintscher, U | 1 |
| Wakino, S | 1 |
| Kim, S | 1 |
| Fleck, E | 1 |
| Hsueh, WA | 1 |
| Law, RE | 1 |
| Chen, HJ | 1 |
| Li, DY | 1 |
| Saldeen, T | 1 |
| Phillips, MI | 1 |
| Sakamoto, H | 1 |
| Aikawa, M | 1 |
| Hill, CC | 1 |
| Weiss, D | 1 |
| Taylor, WR | 1 |
| Libby, P | 1 |
| Lee, RT | 1 |
| Sun, YP | 1 |
| Zhu, BQ | 1 |
| Browne, AE | 1 |
| Pulukurthy, S | 1 |
| Chou, TM | 1 |
| Sudhir, K | 1 |
| Glantz, SA | 1 |
| Deedwania, PC | 1 |
| Chatterjee, K | 1 |
| Parmley, WW | 1 |
| Fischer, JW | 1 |
| Stoll, M | 1 |
| Hahn, AW | 1 |
| Unger, T | 1 |
| Daugherty, A | 1 |
| Manning, MW | 1 |
| Cassis, LA | 1 |
| Lüscher, TF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for losartan and Arteriosclerosis
| Article | Year |
|---|---|
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2004 |
[Hyperuricemia in hypertension].
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Diet, Sodium-Restricte | 2004 |
[Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Pharmacology of ACE inhibitors versus AT1 blockers.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Vascular protection: current possibilities and future perspectives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Clinical Trials as Topic; Cytok | 2001 |
Novel mechanisms linking angiotensin II and early atherogenesis.
Topics: Angiotensin II; Animals; Arteriosclerosis; Humans; Losartan; Models, Cardiovascular; Monocytes; Phen | 2000 |
2 trials available for losartan and Arteriosclerosis
| Article | Year |
|---|---|
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Arteriosclerosis; Brachial Artery; | 2000 |
26 other studies available for losartan and Arteriosclerosis
| Article | Year |
|---|---|
[Is one antihypertensive agent as good as another?].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Drug Therapy, Combination; Humans; Hypertension; Hy | 2002 |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arteriosclerosis; Cells, Cultured; | 2004 |
Upregulation of lectinlike oxidized low-density lipoprotein receptor-1 expression contributes to the vein graft atherosclerosis: modulation by losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Arteriosclerosis; Blotting, Western; End | 2004 |
Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Aortic Diseases; Apolipoproteins | 2005 |
Effects of angiotensin II on connexin 43 of VSMCs in arteriosclerosis.
Topics: Angiotensin II; Animals; Arteriosclerosis; Body Weight; Cholesterol; Connexin 43; Losartan; Male; Mu | 2006 |
[Effects of chronic losartan treatment on myocardial, vascular structure and reactivity with aging in spontaneously hypertensive rats (SHR): its effects compared with those of captopril].
Topics: Aging; Animals; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Captopril; Coronary C | 1995 |
Effect of angiotensin II receptor blocker on angiotensin II stimulated DNA synthesis of cultured human aortic smooth muscle cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Aorta; Arteriosclerosis; Biphenyl Compounds; Cell | 1995 |
The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice.
Topics: Angiotensin Receptor Antagonists; Animals; Apolipoproteins E; Arteriosclerosis; Biphenyl Compounds; | 1997 |
[Physiopathology of angiotensin II and vascular lesion].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteriosclerosis; | 1997 |
Alpha1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice.
Topics: Adrenergic alpha-Antagonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Ap | 1998 |
Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arteriosclerosis; Binding, Competitive; Cell Separ | 1999 |
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Apolipop | 1999 |
Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia.
Topics: Angiotensin Receptor Antagonists; Animals; Arteriosclerosis; Biomarkers; Diet; Hypercholesterolemia; | 2000 |
Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arteriosclerosis; Biological Transport, Active; CD | 2000 |
Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Arteriosclerosis; Body We | 2000 |
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
Topics: Aging; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Aorta, Thor | 2000 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans | 2000 |
Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arteriosclerosis; Cell Line; Cell Movement; CSK Ty | 2001 |
Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Arteriosclerosis; Chemokine CCL2; | 2001 |
Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Apolipoproteins E; Arteriosclerosi | 2001 |
Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Differential regulation of thrombospondin-1 and fibronectin by angiotensin II receptor subtypes in cultured endothelial cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Arteriosclerosis; Blotting, Northe | 2001 |
Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: a possible role for interleukin-6.
Topics: Angiotensin II; Animals; Antibodies; Apolipoproteins E; Arteriosclerosis; CD36 Antigens; Cells, Cult | 2001 |
Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Arteriosclerosis; Drug Syner | 2001 |
Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Abdominal; Arteriosclerosis; Blott | 2002 |